0 19

Cited 0 times in

난치성 부분성 간질환자에서 토피라메이트의 병용투여 효과

DC FieldValueLanguage
dc.contributor.author김원주-
dc.contributor.author이병인-
dc.contributor.author이병인-
dc.date.accessioned2020-07-02T17:13:45Z-
dc.date.available2020-07-02T17:13:45Z-
dc.date.issued1998-
dc.identifier.issn1225-7044-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/176682-
dc.description.abstractBackground : To evaluate the efficacy and safety of topiramate(TPM) as add-on therapy in medically intractable partial epilepsies. Methods : This study was a multicenter double-blind placebo-controlled randomized parallel group trial consisting of 12 weeks of baseline phase, 10 weeks of titration phase, and 8 weeks of maintenance phase. The primary efficacy variable was the median seizure frequency reduction rate(MSFRR) and the other efficacy variables included responder rate, seizure free rate, and global evaluations by the patient and the physician. The patient should have partial epilepsies refractory to the maximally tolerable doses of one to two antiepileptic drugs(AEDs) and should have at least two or more episodes of clinical seizures every 4 weeks during the baseline phase. The target dose of study drugs was 600 mg/day. The study drug was started at the initial dose of 50 mg/day and increased by 50 mg/day every week until 400 mg/day was reached. Thereafter, the dose was increased by 100 mg weekly over next two weeks. Results : A total of 177 patients were randomized into TPM group(n=91) and placebo(PLC) group(n=86). Baseline median seizure frequencies were 5.60 episodes/4 weeks in TPM group and 5.59 episodes/4 weeks in PLC group. Among those who were randomized, 158 patients(TPM: 78 patients, PLC: 80 patients) were available for efficacy measurement by intention-to-treat analysis. The MSFRR was 63.6% for TPM and 17.9% for PLC, which was highly in favor of TPM(p=0.0001). The responder rate was 59.0% for TPM and 23.8% for PLC(p=0.001). Thirteen of 78 patients(16.7%) taking TPM because seizure free compared to 2 of 80 patients(2.5%) taking PLC(p=0.004). The global evaluation by the patient and the physician greatly favored TPM(p=0.001, p=0.001). The incidence of adverse events(AE) was higher in TPM(81.3%) than PLC(48.9%) with CNS-related AE being the most frequent. Among individual AE, anorexia (20.9%) and abdominal pain or discomfort(20.9%) were the most common AE in TPM group. AE precipitated early drop out in 7 patients taking TPM(7.6%) and 3 patients taking PLC(3.5%). No serious AE were observed. Conclusions : TPM was highly effective and safe as add-on therapy in medically intractable partial epilepsies. Slower titration of TPM seems to decrease the drop-out rate but the incidence of AE was still high. The AE profile of TPM in Asians was different from that in Caucasians.-
dc.description.statementOfResponsibilityopen-
dc.languageKorean-
dc.publisher대한신경과학회-
dc.relation.isPartOfJournal of the Korean Neurological Association (대한신경과학회지)-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title난치성 부분성 간질환자에서 토피라메이트의 병용투여 효과-
dc.title.alternativeDouble-Blind Placebo-Controlled Randomized Clinical Trial of Topiramate Add-On Therapy in Medically Intractable Partial Epilepsies-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학교실)-
dc.contributor.googleauthor한국토피라메이트연구팀-
dc.contributor.localIdA00771-
dc.contributor.localIdA02797-
dc.contributor.localIdA02797-
dc.contributor.localIdA02797-
dc.contributor.localIdA02797-
dc.relation.journalcodeJ01836-
dc.contributor.alternativeNameKim, Won Joo-
dc.contributor.affiliatedAuthor김원주-
dc.contributor.affiliatedAuthor이병인-
dc.contributor.affiliatedAuthor이병인-
dc.contributor.affiliatedAuthor이병인-
dc.contributor.affiliatedAuthor이병인-
dc.citation.volume16-
dc.citation.number6-
dc.citation.startPage809-
dc.citation.endPage819-
dc.identifier.bibliographicCitationJournal of the Korean Neurological Association (대한신경과학회지), Vol.16(6) : 809-819, 1998-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.